NEXT day delivery available - 3pm cut off
Worldwide shipping available
Free standard UK delivery on orders over £100
This article is intended for qualified aesthetic practitioners. It is general educational content, not clinical training, and does not replace accredited hands-on instruction or your own clinical judgement.
Nose filler, often marketed to patients as a non-surgical rhinoplasty or "liquid nose job", uses small volumes of hyaluronic acid (HA) filler to camouflage a dorsal hump, support a drooping tip, or even out minor asymmetry. For the practitioner, it is one of the most rewarding treatments in the face and one of the least forgiving. The nose sits on a dense, interconnected arterial network with links to the ophthalmic circulation, and the tissue over the dorsum and tip is thin and tightly bound. Product choice, depth, volume and complication readiness matter more here than almost anywhere else.
This guide covers patient selection, relevant anatomy, choosing a filler for the nose, technique principles, longevity and complication planning, written for UK clinics that already inject and are considering adding, or tightening up, their nasal work.
Filler adds volume. It cannot reduce the size of the nose, remove bone or cartilage, or correct breathing problems. What it does well is change how light falls across the nasal profile, which can make a nose look straighter and better proportioned. Common indications include:
Setting expectations at consultation is half the work. A patient wanting a visibly smaller nose, or one with a large hump, a wide bulbous tip or a markedly deviated nose, is usually better referred for a surgical opinion. Saying no protects the patient and your reputation.
Treat the consultation as a screening exercise. Take a full medical history, including previous rhinoplasty, nasal trauma, prior filler (and which product), autoimmune disease, anticoagulant use and active skin infection. Previous surgery deserves particular caution: scar tissue alters the planes, the vascular supply may have been rerouted, and the skin envelope can be thin and poorly perfused. Many experienced injectors either decline post-rhinoplasty noses or treat them conservatively, in small aliquots, with a long review interval.
Screen for body dysmorphic concerns, document the patient's specific goal in their own words, and take standardised photographs in frontal, lateral, three-quarter and basal views. Your consent should name vascular occlusion, skin necrosis and visual loss explicitly. Given the published data on where these events occur (see below), a vague reference to "bruising and swelling" is not adequate informed consent for nasal work.
The main vessels at risk are the dorsal nasal artery (a terminal branch of the ophthalmic artery), the lateral nasal and angular arteries running along the nasal sidewall, and the columellar artery at the base of the columella. These vessels anastomose freely. Retrograde flow of filler from a nasal branch into the ophthalmic system is the accepted mechanism for filler-related blindness.
Along the dorsum, the main vessels run superficially, within or just above the nasal SMAS. The relatively avascular plane is deep, on the periosteum over the nasal bones and on the perichondrium over the cartilage, kept strictly in the midline. Most nasal techniques depend on staying in that deep midline plane.
The tip skin is thick and sebaceous but tightly adherent, which limits how much volume it will accept before blanching. The columellar artery and branches of the lateral nasal artery supply the tip, so tip and columella injections call for very small volumes, slow delivery and close observation of capillary refill.
The nose needs a product that holds its shape and resists spreading, but in very small volumes. Most practitioners favour a firmer, cohesive, moderately to highly cross-linked HA gel with good lift (high G prime) for the dorsum and radix. Overly soft gels spread laterally and widen the nose; very large-particle, highly projective gels can look lumpy under thin dorsal skin.
When comparing products, consider:
Filler World stocks a range of CE-marked HA fillers indicated for nasal reshaping in our non-surgical rhinoplasty (nose) collection. Firmer gels such as Aqufill Hard are an example of the more structural products some practitioners choose for the dorsum. Always check the manufacturer's instructions for use: not every filler is indicated for the nose, and off-label use shifts more responsibility onto the prescriber and injector.
Training providers teach different approaches, and you should follow the protocol you were assessed on. The principles below are common ground across most of them.
Needle techniques usually involve small, slow boluses placed deep on bone or cartilage in the midline, at the radix, above and below the hump, and at the tip or anterior nasal spine. Many practitioners prefer a blunt cannula for the dorsum, introduced through a single entry point near the tip and advanced in the deep midline plane, because it is less likely to pierce a vessel. A cannula reduces risk but does not remove it, and a fine-gauge cannula can still enter a vessel. Our cannula range and our earlier guide to choosing a cannula for dermal filler cover gauge and length selection in more detail.
The nose consistently appears near the top of published case series of filler-related vision loss. A 2024 review in Aesthetic Surgery Journal identified 365 new cases of partial or complete vision loss after filler injection reported between September 2018 and March 2023, and named the nose (40.6%), forehead (27.7%) and glabella (19.0%) as the highest-risk sites (Doyon et al., 2024). The same review found that most patients with recorded visual outcomes did not recover their vision, which is why prevention and immediate recognition matter so much.
Before you offer nasal filler, make sure your clinic has:
Delayed complications also occur: infection, nodules, and filler migration that widens the bridge or blurs the radix over time. Migration usually reflects too much product, too soft a gel or too superficial a placement, and it is easier to prevent than to correct.
Longevity depends on the product, the volume and the patient's metabolism. In the nose, the low mobility of the dorsum means HA can persist for a long time, and clinic sources commonly quote anywhere from six months to well over a year. Because product may linger longer than patients expect, re-treat only once you have assessed what remains. Stacking new product on residual filler is a common cause of a widened, heavy-looking bridge.
Most trainers class the nose as an advanced area. It is generally better approached after building solid experience in lower-risk areas, with dedicated anatomy and complications training and, ideally, mentored cases.
The result is temporary, it cannot make the nose smaller, and it carries a higher risk profile than many facial areas, including rare but serious vascular events. These points should be covered clearly in consultation and recorded in the consent.
Sometimes, for small residual irregularities, but altered anatomy and scar tissue increase the risk. Many practitioners require a long interval after surgery, liaise with the surgeon and use very small volumes, or decline altogether.
Volumes are typically small, frequently well below 1 ml in a session. Using more is rarely needed and increases both the risk of complications and the chance of an over-filled, widened nose.
Patients usually describe pressure rather than sharp pain. Lidocaine-containing fillers and a gentle technique help, but sudden or severe pain during injection is a warning sign of possible vascular compromise and should prompt you to stop immediately.
Done well, nose filler can give patients a meaningful change with very little product. Done carelessly, it carries some of the most serious risks in aesthetic practice. Careful case selection, a firm and reversible HA gel, a deep midline technique, conservative volumes and a rehearsed complications plan are what separate the two. If you are building your nasal kit, browse our dermal filler range and check each product's IFU for its approved indications before you begin.
